English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

High levels of Wee1 expression have been seen in a variety of malignancies, including breast cancer, cervical cancer and leukaemia. Due to the positive link between cancer and Wee1 expression, the protein has become a particularly relevant therapeutic target in the fight against cancer. The current study aimed to identify potential Wee1 kinase inhibitors from FDA-approved drugs using  in silico  approach. The drug candidates were virtually screened  in silico  against Wee1 kinase using molecular docking. The binding free energy of the nine top-scoring compounds was determined, after which its bioactivity was predicted by three well-validated QSAR models. The molecular dynamics of FDA-approved drugs dasatinib and cangrelor with Wee1 kinase were studied for 100 ns. The results demonstrated that the top-scoring compounds identified as potential Wee1 inhibitors exhibited favourable binding energies (docking scores), and its stability with Wee1 was evident by the binding free energy calculation. The result of the AutoQSAR ensemble/consensus prediction showed that this set of compounds had satisfactory inhibitory attributes. The MD simulation showed stable complexes throughout the duration of the simulation. Based on the data obtained from this study, we recommend the top-scoring compounds for further preclinical investigation for its potential to inhibit Wee1 kinase in cancer.

molecular simulation

Repurposing clinically approved drugs as Wee1 checkpoint kinase inhibitors: an  in silico  investigation integrating molecular docking, ensemble QSAR modelling and molecular dynamics simulation